S&P 500 Industrials Sector SEC Filings — March 12, 2026

12-03-2026

Longeveron Inc. entered a definitive agreement for a private placement raising up to $30M gross proceeds ($15M upfront, additional $15M milestone-driven tied to Phase 2b ELPIS II HLHS trial), led by Coastlands Capital with Janus Henderson Investors, Logos Capital, and Kalehua Capital. Initial proceeds extend cash runway into 4Q26, past anticipated 3Q26 topline data readout for ELPIS II. H.C. Wainwright & Co. acted as exclusive placement agent; securities issued include 6M+ common shares and preferred shares convertible into 22.8M+ shares at $0.52.

• ·Shares priced at $0.52 per share for common stock; Preferred Shares at $1,000 each with $0.52 conversion price
• ·Investors receive 50% interest in net proceeds from potential future Rare Pediatric Disease Priority Review Voucher sale related to HLHS program
• ·Initial closing expected on or about March 11, 2026
• ·Proceeds for clinical/regulatory development of laromestrocel, working capital, and general corporate purposes

12-03-2026

Enanta Pharmaceuticals held its Annual Meeting on March 11, 2026, where stockholders re-elected directors Bruce L.A. Carter, Ph.D. and Jay R. Luly, Ph.D.; approved an amendment to the 2019 Equity Incentive Plan to increase reserved shares by 1,600,000 despite 5,390,888 votes against; approved the say-on-pay proposal; and ratified PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending September 30, 2026. All proposals passed with strong support overall, though the equity plan amendment faced notable opposition representing about 22% of votes cast.

• ·Proposal 1 (Director Elections): Carter - 20,289,217 For, 4,634,123 Withheld; Luly - 24,728,854 For, 194,486 Withheld; 1,929,393 Broker Non-Votes.
• ·Proposal 2: 19,528,223 For, 5,390,888 Against, 4,229 Abstain.
• ·Proposal 3 (Say-on-Pay): 24,228,898 For, 692,079 Against, 2,363 Abstain.
• ·Proposal 4 (Auditors): 26,825,173 For, 26,904 Against, 656 Abstain, 0 Broker Non-Votes.
• ·Definitive proxy statement filed January 26, 2026.

12-03-2026

WM Technology reported Q4 2025 revenue of $43.1 million, down 9.6% YoY from $47.7 million, driven by client churn and ARPU decline to $2,804 from $3,041 amid industry pricing pressures; full-year revenue fell 5.3% YoY to $174.7 million from $184.5 million, though average monthly paying clients rose slightly 2.2% to 5,190. Adjusted EBITDA decreased to $10.4 million in Q4 (down 12.6% YoY) and $39.8 million full-year (down 7.2% YoY), with Q4 net loss of $5.0 million versus prior year income of $3.7 million, but full-year net income remained positive at $3.3 million (down 73% YoY) and cash grew 20% to $62.4 million. The company appointed Nick Rellas to its board effective March 5, 2026, and expects Q1 2026 revenue to decline mid- to high-single digits sequentially from Q4.

• ·Total shares outstanding across Class A and Class V Common Stock: 157.8 million as of December 31, 2025.
• ·Q1 2026 revenue guidance: mid- to high-single digit percentage decline sequentially from Q4 2025.
• ·Conference call: March 12, 2026 at 2:00 p.m. Pacific Time.

12-03-2026

Bimini Capital reported Q4 2025 net income of $3.4 million ($0.34 per share) and full year 2025 net income of $5.8 million ($0.58 per share), marking a turnaround from Q4 2024 loss of $1.5 million and full year 2024 loss of $1.3 million, driven by advisory service revenues rising 30% YoY to $16.6 million from strong Orchid performance. Book value per share increased 85% to $1.26, with stockholders' equity at $12.6 million. However, the MBS portfolio declined 27% YoY to $88.9 million from $122.3 million, total assets fell to $129.7 million from $154.9 million, and the company plans to liquidate most of it for a TJIM acquisition while announcing a $2.5 million share repurchase plan.

• ·Q4 2025 CPR of 16.6% (up from 11.1% Q4 2024 but down from 16.8% Q3 2025)
• ·Effective duration of MBS portfolio 2.229 at Dec 31, 2025 (down from 3.620 at Dec 31, 2024)
• ·Average interest rate spread improved to 1.59% in Q4 2025 from 0.69% Q4 2024
• ·TJIM acquisition expected to close beginning of Q2 2026
• ·Earnings call scheduled for March 13, 2026 at 10:00 AM ET
• ·Share repurchase plan over next 24 months under Rule 10b5-1

12-03-2026

Abacus Global Management reported record Q4 and FY2025 results, with Q4 revenue up 116% YoY to $71.9M, FY revenue up 110% YoY to $235.2M, FY GAAP net income of $36.5M versus prior-year loss of $23.9M, and Adjusted EBITDA up 132% YoY to $38.6M in Q4 with ROIC and ROE above 20%. The company completed the AccuQuote acquisition, approved a $0.20/share dividend and $20M share repurchase program, transferred listing to NYSE (ABX), and initiated FY2026 Adjusted net income guidance of $96-104M. However, Average Realized Gain declined to 27% from 37% in Q3 2025, and FY Adjusted EBITDA margin improved only modestly to 56% from 55% YoY.

• ·Q4 Life Solutions revenue increase of $32.9M YoY; Asset Management +$5.6M YoY; Technology Services +$235K YoY.
• ·Annualized Turnover Ratio Q4 2025: 2.6x (exceeding long-term target of 1.5x-2.0x).
• ·Long-term targets: $450M Adjusted EBITDA at scale, 70% recurring revenue.
• ·FY2026 Adjusted net income outlook: $96-104M (up to 22% growth over FY2025 $85.7M).

12-03-2026

Wearable Devices Ltd. reported revenues of $647K for the year ended December 31, 2025, up 24% YoY from $522K in 2024, driven by growth in North America (up 39% to $385K or 60% of total) and Asia (up 36% to $118K or 18%). However, the company swung to a gross loss of $148K from a $85K profit in 2024 due to higher cost of revenues ($594K, up 64%) and inventory impairment ($201K, up 168%), while operating loss widened 7% to $8.3M and net loss increased 3% to $8.1M amid elevated R&D expenses.

• ·Entered non-exclusive reseller arrangement with Media Exceed Co., Ltd. in Japan in August 2025.
• ·Entered exclusive distribution agreement with Sky Commerce Co., Ltd. in South Korea in October 2025.

12-03-2026

Grayscale Dogecoin Trust ETF (GDOG), sponsored by Grayscale Investments Sponsors, LLC, filed its 10-K for FY ended December 31, 2025, detailing its operations as a passive vehicle holding Dogecoin (DOGE) with 624,700 shares outstanding as of March 6, 2026, and each share representing approximately 117.5835 DOGE. The Trust uplisted on NYSE Arca on November 24, 2025, after which shares traded with an average premium of 0.08% but also an average discount of 0.24% to NAV per share through year-end. Extensive risk factors highlight DOGE price volatility, regulatory uncertainties, and potential for shares to trade at premiums or discounts to NAV.

• ·Trust formed January 27, 2021; operations commenced January 30, 2025.
• ·Name changed to ETF on November 20, 2025; uplisted on NYSE Arca November 24, 2025.
• ·Sponsor changes: Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole sponsor effective May 3, 2025.
• ·SEC approved NYSE Arca generic listing standards September 17, 2025.

12-03-2026

Bath & Body Works reported FY2025 net sales of $7,291M, down 0.2% YoY to $7,307M, driven by a 0.9% increase in stores sales to $5,582M but a 5.4% decline in direct sales to $1,395M, while international sales grew 4.9% to $314M. Reported operating income fell 11% to $1,126M from $1,266M, and net income decreased to $649M from $798M with diluted EPS at $3.11 versus $3.61. However, net cash from operating activities surged 24% to $1,102M, boosting free cash flow 31% to $865M and ending cash balances to $953M.

• ·Adjusted Operating Income declined to $1,156M from $1,266M YoY.
• ·Debt Leverage Ratio increased to 2.7x from 2.5x.
• ·Total ordinary dividends remained flat at $0.80 per share, with total paid $167M vs $177M.
• ·Total Selling Square Feet increased 2% to 5,493 thousand.

12-03-2026

abrdn Global Income Fund, Inc. (NYSE American: FCO) adjourned its Special Shareholder Meeting on March 12, 2026, to April 1, 2026, at 11:30 am Eastern Time, to solicit additional proxies and achieve quorum. Shareholders are voting on an Agreement and Plan of Reorganization with abrdn Asia Pacific Income Fund, Inc. (NYSE American: FAX) and the liquidation and dissolution of FCO, with the Board unanimously recommending approval. Aberdeen Investments reports $525B in assets under management as of December 31, 2025.

• ·Proxy materials available on www.sec.gov

12-03-2026

General Electric Company filed definitive additional proxy soliciting materials (DEFA14A) on March 12, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific proposals, financial data, or performance metrics are detailed in the provided materials.

12-03-2026

LINKBANCORP reported net income of $33.5M for 2025, up 28% YoY from $26.2M, driven by net interest income growth of 4% to $104.3M, higher noninterest income from $11.1M branch sale gain, and loan growth of 13% to $2.53B net. However, provision for credit losses surged to $8.2M from $0.3M, NIM declined to 3.81% from 3.88%, loan yields fell to 6.27% from 6.38%, and noninterest-bearing deposits dropped 8% to $604M.

• ·Securities AFS increased to $262.6M from $145.6M.
• ·Interest-bearing deposits grew to $1.95B from $1.70B.
• ·Shareholders' equity rose to $306.4M from $280.2M.
• ·EPS basic $0.90 vs $0.71.

12-03-2026

Grayscale Bittensor Trust (GTAO), a Delaware Statutory Trust formed on April 30, 2024, issued its 10-K for FY ended December 31, 2025, reporting it holds approximately 0.3% of TAO in circulation with each Share representing ~0.0192 TAO; 1,907,800 Shares were outstanding as of March 6, 2026. Shares traded on OTCQX at substantial premiums to NAV per Share, with a maximum of 124% and average 65% premium from December 12-31, 2025, and 124% as of December 31, 2025, due to lack of redemption program, Rule 144 holding periods, and other factors preventing arbitrage. The Trust filed an S-1 in December 2025 for potential NYSE Arca listing as an ETF with redemption program, though not yet effective.

• ·Trust formed April 30, 2024; Sponsor changed to GSIS effective May 3, 2025 post-Reorganization.
• ·Index changed from Coin Metrics Real-Time Rate to CoinDesk Bittensor Benchmark Rate effective March 6, 2026.
• ·Shares issued in Baskets of 100 to Authorized Participants; currently no redemption program.
• ·Private placements only; OTCQX quoted but not listed on national exchange.

12-03-2026

CACI International Inc entered into a Second Supplemental Indenture on March 12, 2026, issuing $500 million in additional 6.375% Senior Notes due 2033, increasing the total outstanding principal to $1.5 billion. The company received net proceeds of approximately $518 million, intended for repaying revolving credit facility debt used in the ARKA Group L.P. acquisition. The notes are senior unsecured, guaranteed by subsidiaries, with no reported issues in the offering process.

• ·Interest payable semi-annually on June 15 and December 15; first payment for Additional Notes on June 15, 2026, including accrued interest from December 15, 2025.
• ·Notes mature on June 15, 2033.
• ·Issued in private placement to qualified institutional buyers under Rule 144A.
• ·Base Indenture dated June 2, 2025; First Supplemental Indenture dated November 25, 2025.

12-03-2026

60 Degrees Pharmaceuticals, Inc. filed an 8-K on March 12, 2026, announcing an updated legal opinion from Sichenzia Ross Ference Carmel LLP confirming the validity of common shares issuable under its at-the-market (ATM) equity offering program pursuant to the Sales Agreement dated September 5, 2025, with HC Wainwright & Co., LLC, for an aggregate offering price of up to $981,000. The opinion does not alter the terms of the ATM Program and relates to the Registration Statement on Form S-3 (effective July 18, 2024) and prospectus supplement dated March 11, 2026. No financial performance metrics or changes in operations were reported.

• ·Registration Statement on Form S-3 filed July 12, 2024, effective July 18, 2024
• ·Common stock par value $0.0001 per share, traded as SXTP on Nasdaq
• ·Warrants traded as SXTPW on Nasdaq

12-03-2026

California BanCorp's Board of Directors approved a quarterly cash dividend of $0.10 per share on its common stock on March 12, 2026. The dividend will be payable on April 15, 2026, to shareholders of record as of the close of business on March 24, 2026. This routine declaration reflects stable shareholder returns with no comparative financial metrics or performance declines reported.

12-03-2026

Treasure Global Inc.'s subsidiary TADAA Technologies Sdn Bhd entered into a Software Enhancement Agreement on March 11, 2026, with Apexcode Innovations Snd Bhd to provide technology services for enhancing the Tazte Apps platform. The total contract price is RM11.7M (approximately $2.5M USD), with the first milestone payment of RM3.9M (approximately $0.83M USD); deliverables including source code must be handed over within 2 months. No immediate financial impacts or performance metrics are disclosed.

• ·Agreement includes development, upgrade, testing, deployment, and maintenance services per Appendix A
• ·Deliverables must meet Acceptance Criteria in Appendix A and be fully compatible with existing system
• ·Handover of deliverables (source code, object code, etc.) within 2 months from March 11, 2026

12-03-2026

National Beverage Corp reported net sales of $264.6M for the three fiscal months ended January 31, 2026, down 0.9% YoY from $267.1M, while nine-month sales declined 0.5% YoY to $883.4M from $887.7M. However, gross profit rose 0.7% to $99.6M (three months) and 1.1% to $334.3M (nine months), driving operating income up 1.1% to $51.1M and $180.0M respectively, and net income up 3.9% to $41.2M (three months) and 0.9% to $143.3M (nine months). Cash and equivalents surged 62% to $314M, boosting total assets 18% to $792M and shareholders' equity 33% to $591M, though operating cash flow dipped 7% YoY to $136M.

• ·Trade receivables decreased to $97M from $104M year-over-year balance sheet comparison.
• ·Inventories increased to $96M from $85M as of May 3, 2025.
• ·Total liabilities declined 12% to $201M from $229M.
• ·Capital expenditures were $15M for nine months, down from $21M prior year.
• ·No dividends paid on common stock in nine months ended Jan 31, 2026 (prior year: $304M).

12-03-2026

Pioneer Bancorp, Inc./MD reported strong balance sheet growth with total assets increasing 8.7% YoY to $2.15B, net loans up 14.8% to $1.65B, and deposits rising 9.6% to $1.74B at December 31, 2025. Net income for the full year 2025 reached $20.3M with EPS of $0.83, compared to $15.3M and $0.61 EPS for FY 2024 ended June 30. However, non-performing assets more than doubled to $11.3M from $5.2M, pushing non-performing loans to 0.67% of total loans (up from 0.36%) and non-performing assets to 0.52% of total assets (up from 0.27%).

• ·Provision for credit losses was $3.7M for year ended Dec 31, 2025, up from $220K for six months ended Dec 31, 2024.
• ·Non-accrual residential mortgages increased to $3.9M from $4.1M (slight decline), but commercial real estate non-accrual rose to $6.1M from $0.
• ·Shareholders’ equity grew to $324M from $305M YoY.

12-03-2026

Genie Energy Ltd. disclosed that its financial statements for years ended December 31, 2023 and 2024, and unaudited quarterly periods in 2024 and 2025, should not be relied upon due to material misstatements in accounting for its captive insurance subsidiary's liabilities, resulting in understatements of Income from Operations and Net Income; restatements will increase 2023 Net Income by $32.7M and 2024 by $22.9M. However, the issue stems from audit discoveries amid the PCAOB revocation of prior auditor Zwick CPA's registration, and management identified material weaknesses in internal controls over financial reporting as of December 31, 2025. The company plans to include restatements in its upcoming 2025 10-K, delayed via a Form 12b-25 filing by March 16, 2026.

• ·Affected balance sheet items include cash and cash equivalents, restricted cash (short-term and long-term), deferred income tax assets net, income taxes payable, and current/noncurrent captive insurance liabilities.
• ·Restatements to be included in Comprehensive 10-K for fiscal year ended December 31, 2025, rather than separate amended filings.
• ·Preliminary estimates subject to change as review is ongoing.

12-03-2026

Identiv reported Q4 FY2025 net revenue of $6.2M, down 8% YoY from $6.7M due to the exit of lower-margin business, but exceeded guidance with GAAP gross margin surging to 18.1% from -14.9% and non-GAAP net loss from continuing operations narrowing to $3.7M from $4.3M. FY2025 revenue fell 19% YoY to $21.5M from $26.6M, however GAAP gross margin improved to 6.1% from 1.3%, operating expenses declined to $23.5M from $28.3M, and net loss shrank to $18.0M from $25.9M, aided by Thailand production transition. The company signed an exclusive multi-year supply agreement for specialized BLE smart labels and guides Q1 FY2026 revenue at $6.7M-$7.2M.

• ·Q4 FY2025 non-GAAP operating expenses flat at $4.1M YoY.
• ·FY2025 non-GAAP operating expenses slightly down to $17.6M from $17.9M.
• ·Cash and cash equivalents stood at $128.6M as of December 31, 2025, down from $135.6M at year-end 2024.
• ·Conference call scheduled for March 12, 2026, at 5:00 p.m. EDT.

12-03-2026

On March 6, 2026, XBP Americas, LLC, a subsidiary of XBP Global Holdings, Inc., entered into a Limited Waiver and Third Amendment to its ABL Credit Agreement originally dated July 29, 2025, eliminating the covenant requiring minimum excess availability of $7.5M and temporarily increasing the advance rate for eligible investment grade billed accounts to 95.0% through September 30, 2026. However, the amendment introduces a temporary availability block through June 30, 2026, reducing borrowing capacity by the greater of $3.75M or 5.0% of the borrowing base if the fixed charge coverage ratio falls below 1.00 to 1.00, along with adjustments to borrowing base calculation and cash dominion mechanics.

• ·ABL Credit Agreement originally dated July 29, 2025; previously amended by First Amendment on Dec 19, 2025 and Second Amendment on Jan 21, 2026
• ·Fixed charge coverage ratio trigger for availability block: below 1.00 to 1.00
• ·Temporary availability block effective through June 30, 2026; advance rate increase through Sep 30, 2026

12-03-2026

American Public Education, Inc. (APEI) reported FY2025 revenue of $648.9M, up 3.9% YoY from $624.6M in FY2024, with strong growth in RU segment (+13.9% to $246.2M) and HCN (+11.4% to $75.0M), but APUS grew only 0.9% to $319.8M (flat) and Corporate/Other declined 67.4% to $7.8M. Net income improved to $31.6M (4.8% margin) from $16.1M (2.6% margin), with operating income up 45.0% to $47.9M; however, total assets fell to $521.4M from $570.1M amid preferred stock redemption and asset sales. Diluted EPS rose to $1.36 from $0.55, while cash and equivalents increased to $176.5M.

• ·Operating cash flow increased to $62.0M in FY2025 from $48.9M in FY2024.
• ·Net cash used in financing activities was $49.2M in FY2025, primarily due to $43.2M preferred stock redemption.
• ·Accumulated deficit improved to $16.5M as of Dec 31, 2025 from $41.8M as of Dec 31, 2024.
• ·Long-term debt increased slightly to $94.7M as of Dec 31, 2025 from $93.4M.
• ·Loss on sale of subsidiary: $3.9M in FY2025.

12-03-2026

Analog Devices, Inc. held its 2026 Annual Meeting of Shareholders on March 11, 2026, resulting in the election of all ten director nominees with strong shareholder support (ranging from approximately 93% to 99% votes for). Key management proposals passed overwhelmingly, including advisory approval of named executive officer compensation (90% for), ratification of Ernst & Young LLP as auditors for fiscal year ending October 31, 2026, and approval of the Amended and Restated 2020 Equity Incentive Plan (95% for). However, the non-binding shareholder proposal on special meeting rights was rejected, receiving only 38% support.

• ·Proxy statement filed with SEC on January 23, 2026; Plan adopted by Board on December 10, 2025
• ·Broker non-votes: 30,319,338 shares across relevant proposals

12-03-2026

Glacier Bancorp, Inc. (GBCI) issued its DEF 14A proxy statement dated March 12, 2026, for the Annual Meeting on April 29, 2026, proposing the election of 10 directors, an advisory vote on executive compensation, and ratification of Forvis Mazars, LLP as independent auditors for the fiscal year ending December 31, 2026. As of the record date February 26, 2026, there were approximately 130,107,508 shares of common stock outstanding. Principal shareholders as of December 31, 2025, include BlackRock, Inc. (14,183,609 shares, 10.9%) and The Vanguard Group, Inc. (12,350,033 shares, 9.5%).

• ·Annual Meeting location: The Hilton Garden Inn, 1840 Highway 93 South, Kalispell, Montana, at 9:00 a.m. Mountain Time.
• ·Proxy solicitation deadline: 11:59 p.m. Eastern Time on April 28, 2026.
• ·Subsidiary divisions include Altabank, First State Bank, Bank of the San Juans, and others.

12-03-2026

Hanover Bancorp, Inc. completed a $35M private placement of fixed-to-floating rate subordinated notes due 2036 to qualified institutional buyers and accredited investors, with initial semi-annual interest at 7.25% until March 15, 2031, then resetting quarterly to 3-month SOFR plus 386 basis points. The Notes, rated BBB+ by Egan-Jones Ratings Company, qualify as Tier 2 capital and will fund the redemption of $25M existing subordinated notes at a lower rate, plus general corporate purposes including equity contributions to Hanover Community Bank. CEO Michael Puorro stated this enhances financial flexibility, capital base, and supports balance sheet growth.

• ·Notes payable semi-annually and intended to qualify as Tier 2 regulatory capital
• ·Piper Sandler & Co. as lead placement agent; Hovde Group, LLC as co-placement agent

12-03-2026

Angel Studios reported record Q4 2025 revenue of $109.9M, up 254.3% YoY from $31.0M, and full-year revenue of $321.6M, up 233.2% YoY from $96.5M, driven by Angel Guild recurring revenue which grew 488.3% YoY to represent 65.2% of total revenue and membership reaching 2.2M. However, net loss widened to $78.6M in Q4 (from $37.2M) and $170.5M for the year (from $88.4M), due to sharply higher selling and marketing expenses of $120.6M in Q4 (up from $38.0M), while gross margin improved slightly to 60% from 58%. The company anticipates Adjusted EBITDA loss narrowing to less than $25M in 2026 amid content expansion.

• ·Total assets grew to $241.4M from $111.4M YoY, but total liabilities surged to $267.2M from $94.7M, resulting in negative stockholders' equity of -$25.8M vs. positive $16.7M prior year.
• ·Guild membership grew from 550K at end of Q4 2024 to 2.0M in Q4 2025 and 2.2M quarter-to-date.
• ·Plans to double streaming library by adding 200 films and 500+ TV episodes/specials; expect 730 titles by end of 2026.
• ·Upcoming releases: Animal Farm (May 1, 2026), Young Washington (July 3, 2026), Zero A.D. (Q4 2026).

12-03-2026

Blue Ridge Bankshares, Inc. (NYSE American: BRBS) announced the retirement of President and CEO G. William Beale effective March 6, 2026, following his successful leadership in exiting the OCC Consent Order in November 2025 and restoring profitability to Blue Ridge Bank. The Boards appointed Harry Golliday, Executive Vice President and Chief Credit Officer since January 2024, as Interim CEO and President of both the Company and the Bank. This transition positions the Bank to pursue growth and strategic opportunities amid a strengthened financial condition.

• ·G. William Beale joined Blue Ridge Bank as CEO on May 7, 2023, and was appointed President and CEO of the Company on July 12, 2023.
• ·Harry Golliday has over four decades of experience in financial services and joined Blue Ridge Bank in 2024.
• ·G. William Beale turned 76 in December 2025.

12-03-2026

Artificial Intelligence Technology Solutions Inc. completed a 100-for-1 reverse stock split processed by FINRA on March 12, 2026, after which its Board of Directors unanimously voted not to proceed with a proposed Authorized Share Increase of 3.8B common shares filed via Definitive Information Statement on March 2, 2026. The authorized capitalization remains unchanged at 27.52B total shares, including 27.5B common shares and 20M preferred shares. No other material changes or performance metrics were reported.

• ·Reverse Stock Split ratio of 100 for 1 processed by FINRA on March 12, 2026

12-03-2026

Health Catalyst, Inc. reported total revenue of $311.1M for the year ended December 31, 2025, up 1.5% YoY from $306.6M in 2024, with Technology segment revenue growing 6.9% to $208.3M while Professional Services revenue declined 8.0% to $102.9M. Adjusted EBITDA improved significantly 58.6% to $41.4M, and gross margin expanded to 39% from 37%, but net loss widened dramatically to $178.0M from $69.5M, driven by a $110.2M impairment of goodwill and intangible assets. Adjusted gross margin rose to 51% from 49%.

• ·Operating expenses totaled $312.5M in 2025, down from $210.6M in 2024 but elevated due to $110.2M impairment.
• ·Stock-based compensation expense decreased to $27.0M in 2025 from $40.1M in 2024.
• ·Sales and marketing expenses $52.5M in 2025, down from $54.4M in 2024; R&D $49.8M down from $57.9M.

12-03-2026

loanDepot, Inc. reported total net revenues of $1.19B for 2025, up 12.2% YoY from $1.06B, driven by a 15.6% increase in gain on origination and sale of loans to $742.4M and origination income up 60.1% to $131.7M. However, the company recorded a net loss attributable to loanDepot of $62.6M, improved 36.3% from $98.3M prior year, with purchase loan originations declining 6.2% to $15.2B while refinance originations surged 36% to $11.3B; servicing fee income fell 9.2% to $437.2M and total expenses edged up 0.6%. Total loan originations rose 8.1% to $26.5B, but the servicing portfolio UPB grew modestly 2.7% to $119.1B amid rising 60+ day delinquencies to 1.60% from 1.57%.

• ·Licensed loan officers declined to 1,599 from 1,728 YoY.
• ·Headcount reduced to 4,506 from 4,675 YoY.
• ·Total assets grew 8.1% to $6.86B, but equity fell 23.8% to $386M.
• ·Adjusted total revenue $1.21B in 2025 vs $1.10B in 2024.
• ·Adjusted net loss $65.6M in 2025 vs $94.8M in 2024.

12-03-2026

For the year ended December 31, 2025, Opus Genetics reported license and collaboration revenue of $14.2M, up 29% YoY from $11.0M, and total operating expenses declined 28% to $52.8M mainly due to the absence of $28.0M in acquired in-process R&D expenses from 2024, narrowing the net loss to $49.6M from $57.5M. However, R&D expenses increased 15% to $30.8M, G&A rose 21% to $22.0M, operating cash use worsened 38% to $35.3M, and a $11.5M negative fair value change in warrant liabilities further impacted results.

• ·Net cash provided by financing activities increased to $50.0M in 2025 from $4.2M in 2024.
• ·Fair value change in warrant and other derivative liabilities was a $11.5M loss in 2025 versus $0.1M gain in 2024.
• ·Other income, net declined to $2.0M in 2025 from $4.5M in 2024.

12-03-2026

VAALCO Energy reported FY2025 production of 16,556 NRI BOEPD and sales of 17,452 NRI BOEPD, exceeding updated guidance, with Adjusted EBITDAX of $173.4M and net cash from operations of $212.7M; Q4 sales hit 18,566 NRI BOEPD (10% above high-end guidance) and Adjusted EBITDAX of $42.9M, up from Q3's $23.7M. However, FY net loss was $41.4M, Q4 net loss $58.6M (driven by $67.2M impairment on Canadian assets), proved reserves declined 5% YoY to 43.0 MMBOE (66% replacement ratio), and Q4 Adjusted EBITDAX fell from Q4 2024's $76.2M. The company acquired 70% WI in CI-705 block, entered a $255M reserves-based lending facility (expandable to $300M), divested Canadian assets for $25.5M, and guided 2026 capex at $290-360M.

• ·Egypt receivables reduced from $113M at start of 2025 to $31M year-end despite $129M invoiced revenue.
• ·Acquired 70% WI and operatorship of CI-705 block (2,300 km² offshore Côte d’Ivoire).
• ·Divested all Canadian properties (1,850 BOEPD) for $25.5M, closing Feb 19, 2026.
• ·2026 quarterly dividend $0.0625 per share, payable March 27, 2026.
• ·Egypt exploration well initial flow rate ~450 BOEPD.
• ·Kossipo-2A appraisal well tested >7,000 BOPD.

12-03-2026

M3-Brigade Acquisition V Corp., a SPAC, reported net income of $5.8M for the full year ended December 31, 2025, up from $5.2M for the period from inception (March 12, 2024) through December 31, 2024, driven by higher interest income of $12.3M from the Trust Account which grew to $306.9M. However, operating costs surged to $6.5M from $0.5M, resulting in a larger operating loss, increased total liabilities to $20.7M from $14.1M, and a worsened shareholders' deficit of $(19.4M) from $(12.9M). Class A EPS declined to $0.16 from $0.24.

• ·Sponsor would hold 20% of Class A ordinary shares if Class B converted.
• ·Redemption value per Class A share: $10.67 (2025) vs $10.25 (2024).

12-03-2026

NovaBay Pharmaceuticals, Inc. adopted its Second Amended and Restated Certificate of Incorporation on March 12, 2026, authorizing a total of 5,005,000,000 shares, consisting of 5,000,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock, each with a par value of $0.01. The amendment restates governance provisions including a classified board structure, director vacancy fillings, stockholder action by written consent, and supermajority voting requirements for certain bylaw and certificate amendments. No financial performance metrics, period-over-period changes, or operational updates were included.

• ·Original Certificate of Incorporation filed April 19, 2010.
• ·Registered office: 1209 Orange Street, City of Wilmington, County of New Castle, 19801, Delaware.

12-03-2026

Traeger, Inc. stockholders approved amendments to its Certificate of Incorporation on March 2, 2026, enabling a reverse stock split at a ratio between 1-for-10 and 1-for-50; on March 12, 2026, the Board selected and approved a 1-for-50 ratio, abandoning other options. The reverse stock split is expected to become effective at 5:00 p.m. ET on March 17, 2026, with common stock trading on a split-adjusted basis under 'COOK' on the NYSE starting March 18, 2026, and a new CUSIP of 89269P202. No fractional shares will be issued; instead, cash payments will be made based on the split-adjusted closing price on March 17, 2026.

• ·Reverse stock split ratio range approved by stockholders: 1-for-10 to 1-for-50
• ·New CUSIP number post-split: 89269P202
• ·Par value and other terms of common stock unchanged by split
• ·Filing references NYSE non-compliance notice and risks to listing standards

12-03-2026

Littelfuse, Inc. (LFUS) filed a DEFA14A Definitive Additional Proxy Materials on March 12, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and was submitted by the registrant. No substantive proxy details, financial metrics, or shareholder proposals are included in the provided header.

• ·Filing categorized as Definitive Additional Materials under Schedule 14A.

12-03-2026

On March 9, 2026, FedEx Corporation's Board of Directors approved amendments to its FY25–FY27 and FY26–FY28 long-term incentive plans (LTI Plans) to address the impact of the planned FedEx Freight spin-off on June 1, 2026, and the shift in fiscal year end from May 31 to December 31 effective the same date. The amendments measure actual performance through FY26 and assume 100% target performance for remaining periods, resulting in weighted payouts of 67% actual/33% target for FY25–FY27 and 33% actual/67% target for FY26–FY28. These changes apply to named executive officers (NEOs) and other employees remaining with the company post-spin-off, with no alterations to underlying performance metrics.

• ·Amendments approved by Compensation and Human Resources Committee recommendation
• ·Payouts for FY25–FY27 after May 31, 2027; for FY26–FY28 after May 31, 2028
• ·Details on LTI Plans in 2025 Proxy Statement filed August 18, 2025, pages 55-60

12-03-2026

First Northwest Bancorp reported total loans receivable of $1.63B as of December 31, 2025, with a weighted average rate of 5.77%; however, net loan activity was negative $70M in 2025 versus positive $31M in 2024, reflecting lower originations ($213M, -8% YoY) and purchases ($78M, -12% YoY) alongside higher repayments. Nonperforming assets improved to $24M from $30.5M YoY (-21%), while total borrowings at period-end declined to $308M from $336M (-8%). Securities available-for-sale showed a fair value of $270M against amortized cost of $296M, indicating unrealized losses.

• ·Fixed-rate loan originations remained flat at $42M in 2025 vs $41M in 2024.
• ·Adjustable-rate loan originations declined to $171M from $191M YoY.
• ·Partnerships with Woodside for auto loans ($62M purchased in 2025) and Triad Financial Services for manufactured homes ($12M purchased in 2025).
• ·Nonperforming assets decrease primarily due to Water Station loans settlement.

12-03-2026

Mid Penn Bancorp reported net income of $56.2M for 2025, up 13.8% YoY from $49.4M, with net interest income rising 27.1% to $199.1M driven by loan growth and higher NIM of 3.56% (up from 3.11%). However, diluted EPS declined 12.1% to $2.55, ROE fell to 7.70% from 8.61%, and noninterest expenses surged 29.5% to $152.3M largely due to $11.5M in merger costs and higher salaries. Asset growth was strong with average total assets at $6.03B (up 11.5% YoY), though nonperforming assets ratio increased to 0.50%.

• ·Dividends declared increased to $0.84 per share in 2025 from $0.80.
• ·Net charge-offs to average loans rose to 0.029% in 2025 from 0.019%.
• ·Income from fiduciary and wealth management activities up 13.2% to $5.3M.
• ·Net gain on sales of SBA loans declined 36.6% to $220K.
• ·Software licensing expense up 35.1% to $12.6M.
• ·FDIC assessment decreased 17.2% to $3.5M.

12-03-2026

Tonix Pharmaceuticals reported FY2025 product revenue of $13.1M, up 30% YoY from $10.1M, driven by TONMYA launch ($1.4M), Zembrace Symtouch (+9% to $9.3M), and Tosymra (+53% to $2.4M); cash and equivalents surged to $207.6M from $98.8M, boosting total assets to $277.2M. However, net loss was $124M (improved 5% YoY from $130M but still substantial), operating expenses rose due to SG&A jumping 119% to $87.7M amid commercialization efforts, and operating cash burn worsened to $99.8M from $60.9M.

• ·Term loans fully extinguished (short-term and long-term both $0 in 2025 vs $2.8M and $4.7M in 2024).
• ·Inventory declined to $6.0M from $8.4M as of Dec 31.
• ·Common shares issued/outstanding increased to 12.8M from 4.4M, reflecting significant dilution.
• ·FDA approval for TONMYA in August 2025; U.S. launch in November 2025.

12-03-2026

NewMarket Corporation's DEF 14A proxy statement outlines the 2026 Annual Meeting of Shareholders on April 23, 2026, seeking votes to elect seven director nominees, including newly appointed Bruce R. Hazelgrove III following Bruce C. Gottwald's retirement on December 9, 2025, ratify PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approve executive compensation on an advisory basis (say-on-pay). As of the record date February 24, 2026, 9,395,455 shares of common stock were outstanding, with each share entitled to one vote. No period-over-period financial performance data or compensation metrics are detailed in the provided filing content.

• ·Annual Meeting details: Thursday, April 23, 2026 at 10:00 a.m. EDT, The Foundry Building, 500 Tredegar St., Richmond, Virginia 23219.
• ·Record date: close of business on February 24, 2026.
• ·Proxy materials available via Internet; paper copies orderable by April 13, 2026.
• ·Bruce R. Hazelgrove, III appointed to Board effective February 26, 2026, and to the Executive Committee.
• ·Voting requirements: majority of votes cast for director elections, ratification of auditor, and say-on-pay; abstentions and broker non-votes generally have no effect.

12-03-2026

Avery Dennison Corporation's 2026 Proxy Statement outlines the virtual Annual Meeting on April 30, 2026, seeking approval for election of 10 directors, advisory vote on executive compensation, ratification of PwC as auditors, and opposition to a stockholder proposal for an independent Board Chairman. In 2025, the company achieved strong capital allocation with $572.3M in share repurchases, $288.4M in dividends, $200.4M capex, and a $390M acquisition of Taylor Adhesives, alongside over $60M in restructuring savings; however, base businesses faced a weaker sales environment requiring productivity actions to protect margins, and Intelligent Labels grew only low-single digits amid tariff-related volume impacts.

• ·Annual Meeting at 12:00 p.m. ET on April 30, 2026, virtually at www.virtualshareholdermeeting.com/AVY2026
• ·Board recommends FOR Proposals 1-3, AGAINST Proposal 4 (independent Board Chairman)
• ·Company segments: Materials Group and Solutions Group
• ·High-value products now ~45% of revenue mix after driving disproportionate growth

12-03-2026

Stoneridge reported FY2025 sales of $861.3M and adjusted EBITDA of $25.0M (2.9% margin), outperforming end-markets by 150 bps driven by MirrorEye growth of 69% to $111M, material cost improvements of 80 bps, and $6.6M reduction in quality costs. However, Electronics sales declined 7.3% YoY to $551.4M, Control Devices sales fell 6.2% to $277.9M, and the company posted a net loss of $102.8M due to $21.6M asset impairment and $44.5M tax valuation allowances. Guidance includes 2026 revenue of $625-650M (4.2% growth ex-Control Devices) and EBITDA of $20-25M, with 2027 targets of $715M revenue and $44M EBITDA, alongside a CEO transition to Natalia Noblet effective April 1, 2026.

• ·Cash and equivalents $66.3M, total debt $180.9M, net debt $114.7M as of Dec 31, 2025.
• ·Adjusted net debt $137.7M, TTM adjusted EBITDA $39.8M, leverage ratio 3.46x (covenant max 3.75x).
• ·Credit facility maturity extended to July 1, 2027.
• ·2030 targets: revenue $850M-$1B, EBITDA $80-120M (9.5%-12.0% margin).
• ·Q4 adjusted EBITDA $3.4M (1.7% of sales); FY adjusted EBITDA margin 2.9%.